vVardis Reports Revenue Growth Ahead of US Listing

VVardis, a Swiss company specializing in dental treatments, announced that its revenues trebled in the first half of 2026, reaching $28.6 million, despite recording a net loss of $27.8 million. The company is focused on developing non-surgical treatments for early caries and plans to use the proceeds from its initial public offering to finance its operations, with the intention of listing its shares on the New York Stock Exchange under the symbol VVVV. This move comes at a time when the US market is being selective and cautious, although healthcare companies remain relatively unaffected by the economic crisis.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل